亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 氯普噻噸 CAS: 113-59-7
氯普噻噸 CAS: 113-59-7
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 113-59-7
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
氯普噻噸
CAS: 113-59-7
中文別名: 泰爾登; 氯丙硫蒽; 氯丙硫新; 反式-2-氯-9-(3-二甲胺基亞丙基)硫雜蒽; (Z)N,N-二甲基-3-(2-氯9H-亞噻噸基)-1-丙胺 
英文名稱: chlorprothixene
英文別名: 2-chloro-3-(dibenzo(b,e)thiin-10-ylidene)propyldimethylamine; Tardan
EINECS號: 204-032-8
分子式: C18H18ClNS
分子量: 315.86 
熔點:96-99℃
質量:企標
含量:99%
性狀:淡黃色結晶性粉末;無臭、無味
包裝規格:25KG/紙板桶
產品用途: 為硫雜蒽類抗精神病藥 抗精神病作用不及氯丙嗪,但鎮靜作用較氯丙嗪強,抗腎上腺素作用及抗膽堿作用弱 。伴有抑郁或焦慮癥狀的精神分裂癥、躁狂癥、更年期精神病及神經官能癥等
包裝;25kg/桶
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31078  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |